Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer
Abstract Human epidermal growth factor receptor-2 (HER2)-targeting drugs are increasingly being incorporated into therapeutic paradigms for non-breast cancers, yet studies on HER2 expression in ovarian cancer (OC) are inadequate. Here, we studied the HER2 status and dynamic changes in OC by reviewin...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-57515-y |
| _version_ | 1797219822662057984 |
|---|---|
| author | Yoo-Na Kim Yun Soo Chung Eunhyang Park Seung Tae Lee Jung-Yun Lee |
| author_facet | Yoo-Na Kim Yun Soo Chung Eunhyang Park Seung Tae Lee Jung-Yun Lee |
| author_sort | Yoo-Na Kim |
| collection | DOAJ |
| description | Abstract Human epidermal growth factor receptor-2 (HER2)-targeting drugs are increasingly being incorporated into therapeutic paradigms for non-breast cancers, yet studies on HER2 expression in ovarian cancer (OC) are inadequate. Here, we studied the HER2 status and dynamic changes in OC by reviewing the records of patients who underwent HER2 testing at a single institution. Clinical parameters, including histology, BRCA status, and immunohistochemistry (IHC), were evaluated alongside HER2 expression, timing, and anatomical location. Among 200 patients, 28% and 6% exhibited expression scores of 2+ and 3+, respectively. HER2 3+ scores were observed in 23%, 11%, 9%, and 5% of mucinous, endometrioid, clear cell, and high-grade serous tumors, respectively, and were exclusively identified in BRCA-wildtype, mismatch repair-proficient, or PD-L1-low-expressing tumors. The TP53 mutation rate was low, whereas ARID1A, KRAS, and PIK3CA mutations were relatively more prevalent with HER2 scores of 2+ or 3+ than with 0 or 1+. Four of the five tumors with an HER2 3+ score exhibited ERBB2 amplification. Among 19 patients who underwent multiple time-lagged biopsies, 11 showed increased HER2 expression in subsequent biopsies. Patients with HER2-overexpressing OC exhibited distinct histological, IHC, and genomic profiles. HER2-targeting agents are potential options for BRCA-wildtype patients, particularly as later lines of treatment. |
| first_indexed | 2024-04-24T12:39:45Z |
| format | Article |
| id | doaj.art-c1ea68d0727543d19019f0aabc197b49 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-24T12:39:45Z |
| publishDate | 2024-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-c1ea68d0727543d19019f0aabc197b492024-04-07T11:18:42ZengNature PortfolioScientific Reports2045-23222024-04-011411910.1038/s41598-024-57515-yHuman epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancerYoo-Na Kim0Yun Soo Chung1Eunhyang Park2Seung Tae Lee3Jung-Yun Lee4Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of MedicineDepartment of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of MedicineDepartment of Pathology, Yonsei University College of MedicineDepartment of Laboratory Medicine, Yonsei University College of MedicineDepartment of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of MedicineAbstract Human epidermal growth factor receptor-2 (HER2)-targeting drugs are increasingly being incorporated into therapeutic paradigms for non-breast cancers, yet studies on HER2 expression in ovarian cancer (OC) are inadequate. Here, we studied the HER2 status and dynamic changes in OC by reviewing the records of patients who underwent HER2 testing at a single institution. Clinical parameters, including histology, BRCA status, and immunohistochemistry (IHC), were evaluated alongside HER2 expression, timing, and anatomical location. Among 200 patients, 28% and 6% exhibited expression scores of 2+ and 3+, respectively. HER2 3+ scores were observed in 23%, 11%, 9%, and 5% of mucinous, endometrioid, clear cell, and high-grade serous tumors, respectively, and were exclusively identified in BRCA-wildtype, mismatch repair-proficient, or PD-L1-low-expressing tumors. The TP53 mutation rate was low, whereas ARID1A, KRAS, and PIK3CA mutations were relatively more prevalent with HER2 scores of 2+ or 3+ than with 0 or 1+. Four of the five tumors with an HER2 3+ score exhibited ERBB2 amplification. Among 19 patients who underwent multiple time-lagged biopsies, 11 showed increased HER2 expression in subsequent biopsies. Patients with HER2-overexpressing OC exhibited distinct histological, IHC, and genomic profiles. HER2-targeting agents are potential options for BRCA-wildtype patients, particularly as later lines of treatment.https://doi.org/10.1038/s41598-024-57515-y |
| spellingShingle | Yoo-Na Kim Yun Soo Chung Eunhyang Park Seung Tae Lee Jung-Yun Lee Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer Scientific Reports |
| title | Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer |
| title_full | Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer |
| title_fullStr | Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer |
| title_full_unstemmed | Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer |
| title_short | Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer |
| title_sort | human epidermal growth factor receptor 2 expression and subsequent dynamic changes in patients with ovarian cancer |
| url | https://doi.org/10.1038/s41598-024-57515-y |
| work_keys_str_mv | AT yoonakim humanepidermalgrowthfactorreceptor2expressionandsubsequentdynamicchangesinpatientswithovariancancer AT yunsoochung humanepidermalgrowthfactorreceptor2expressionandsubsequentdynamicchangesinpatientswithovariancancer AT eunhyangpark humanepidermalgrowthfactorreceptor2expressionandsubsequentdynamicchangesinpatientswithovariancancer AT seungtaelee humanepidermalgrowthfactorreceptor2expressionandsubsequentdynamicchangesinpatientswithovariancancer AT jungyunlee humanepidermalgrowthfactorreceptor2expressionandsubsequentdynamicchangesinpatientswithovariancancer |